Published in Exp Neurol on October 29, 2007
Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics (2009) 1.36
Neuritic dystrophy and neuronopathy in Akita (Ins2(Akita)) diabetic mouse sympathetic ganglia. Exp Neurol (2008) 1.02
The effect of erythropoietin on normal and neoplastic cells. Biologics (2012) 0.98
Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain (2009) 0.97
Schwann cells as a therapeutic target for peripheral neuropathies. CNS Neurol Disord Drug Targets (2010) 0.92
Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol (2011) 0.90
Erythropoietin: still on the neuroprotection road. Ther Adv Neurol Disord (2012) 0.90
Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin. Mol Ther (2010) 0.90
Therapeutic Potential of Adipose-Derived SSEA-3-Positive Muse Cells for Treating Diabetic Skin Ulcers. Stem Cells Transl Med (2015) 0.83
A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes. Exp Diabetes Res (2011) 0.82
Prolonged regulatable expression of EPO from an HSV vector using the LAP2 promoter element. Gene Ther (2011) 0.82
Carbamylated erythropoietin attenuates cardiomyopathy via PI3K/Akt activation in rats with diabetic cardiomyopathy. Exp Ther Med (2013) 0.76
Neuroprotection and CD131/GDNF/AKT Pathway of Carbamylated Erythropoietin in Hypoxic Neurons. Mol Neurobiol (2016) 0.75
Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med (2006) 17.55
Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 10.65
Diabetic autonomic neuropathy. Diabetes Care (2003) 6.59
Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol (2006) 5.56
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A (2000) 5.20
Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (2004) 4.09
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A (2001) 3.80
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A (2004) 3.40
The natural history of diabetic autonomic neuropathy. Q J Med (1980) 3.36
Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci U S A (1996) 2.77
Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol (1994) 2.75
Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci (2005) 2.32
Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A (2004) 1.65
Erythropoietin for neurologic protection and diabetic neuropathy. N Engl J Med (2004) 1.61
Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure. Clin Auton Res (2002) 1.61
Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med (1999) 1.59
Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients? Diabet Med (2004) 1.47
Effects of insulin, insulin-like growth factor-II, and nerve growth factor on neurite formation and survival in cultured sympathetic and sensory neurons. J Neurosci (1986) 1.47
Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care (2001) 1.42
Pathology of autonomic neuropathy in diabetes mellitus. Ann Intern Med (1980) 1.39
Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med (1998) 1.34
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol (2004) 1.28
Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.26
Diabetic autonomic neuropathy. Diabetes (1978) 1.25
Anemia and the role of erythropoietin in diabetes. J Diabetes Complications (2006) 1.22
Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms. J Neurosci Res (2006) 1.20
Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy: a new experimental model of diabetic autonomic neuropathy. Am J Pathol (2003) 1.16
Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Mol Cell Neurosci (2005) 1.15
Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res (1997) 1.14
Treatment of orthostatic hypotension with erythropoietin. N Engl J Med (1993) 1.13
Anemia and diabetes in the absence of nephropathy. Diabetes Care (2005) 1.13
Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res (1995) 1.10
Effect of diabetes and aging on human sympathetic autonomic ganglia. Am J Pathol (1993) 1.09
The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med (1994) 1.09
Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A (2004) 1.08
Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q J Med (1990) 1.07
Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis (2006) 1.06
Erythropoietin use in cancer patients: a matter of life and death? J Clin Oncol (2005) 1.03
Biochemical characterization of programmed cell death in NGF-deprived sympathetic neurons. J Neurobiol (1992) 1.03
Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J Neuropathol Exp Neurol (2004) 0.97
Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin Auton Res (2002) 0.95
Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy. Am J Pathol (1999) 0.95
Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci Lett (2004) 0.94
Erythropoietin: high profile, high scrutiny. J Clin Oncol (2007) 0.94
Near nerve local insulin prevents conduction slowing in experimental diabetes. Brain Res (1997) 0.93
Neuroprotection in the peripheral nervous system: rationale for more effective therapies. Arch Neurol (2006) 0.93
Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet Med (2002) 0.93
Abnormal PI3 kinase/Akt signal pathway in vagal afferent neurons and vagus nerve of streptozotocin-diabetic rats. Brain Res Mol Brain Res (2003) 0.90
The effect of pancreatic islet transplantation and insulin therapy on experimental diabetic autonomic neuropathy. Diabetes (1983) 0.90
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer (2007) 0.89
Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation. Eur J Neurosci (2007) 0.88
Ultrastructural and biochemical characterization of autonomic neuropathy in rats with chronic streptozotocin diabetes. J Neuropathol Exp Neurol (1986) 0.86
Blunted erythropoietin response to anemia in patients with Type 1 diabetes. Diabetes Metab Res Rev (2000) 0.85
The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med (1998) 0.82
Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations. Horm Res (2004) 0.80
Erythropoietin use and abuse: When physiology and pharmacology collide. Adv Exp Med Biol (2001) 0.79
Erythropoietin production after renal denervation or beta-adrenergic blockade. Am J Physiol (1976) 0.79
Erythropoietin, glutamate, and neuroprotection. N Engl J Med (2004) 0.79
Blunted erythropoietin response to anemia in type 1 diabetic patients. Diabetes Care (1999) 0.78
Dual-action peptides: a new strategy in the treatment of diabetes-associated neuropathy. Drug Discov Today (2006) 0.77
Autonomic dysfunction and anemia in neurologic disorders. J Auton Nerv Syst (1996) 0.76
Erythropoietin treatment of postural hypotension in anemic type 1 diabetic patients with autonomic neuropathy: a case study of four patients. Diabetes Care (2001) 0.76
The influence of the autonomic nervous system in the control of erythropoietin secretion in the hypoxic rat. J Physiol (1977) 0.76
Successful treatment of severe orthostatic hypotension with erythropoietin. Pacing Clin Electrophysiol (2003) 0.76
Coefficient of variation of R-R intervals in electrocardiogram is a sensitive marker of anemia induced by autonomic neuropathy in type 1 diabetes. Diabetes Res Clin Pract (2007) 0.76
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Autophagosome-independent essential function for the autophagy protein Atg5 in cellular immunity to intracellular pathogens. Cell Host Microbe (2008) 4.16
Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (2004) 4.09
Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med (2002) 3.87
An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 3.60
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
Reducing door-to-needle times using Toyota's lean manufacturing principles and value stream analysis. Stroke (2012) 2.43
Genome sequence of Cronobacter sakazakii BAA-894 and comparative genomic hybridization analysis with other Cronobacter species. PLoS One (2010) 2.41
Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med (2003) 2.37
Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A (2003) 2.28
Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A (2002) 2.16
Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A (2009) 2.14
Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2002) 2.08
HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol (2009) 2.08
Identification of novel brain biomarkers. Clin Chem (2006) 2.06
Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem (2006) 1.98
Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A (2003) 1.88
Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes. Stroke (2013) 1.80
Imaging of functional connectivity in the mouse brain. PLoS One (2011) 1.76
Diagnostic considerations in the measurement of human chorionic gonadotropin in aging women. Clin Chem (2005) 1.71
Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A (2002) 1.66
Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci (2006) 1.65
Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A (2004) 1.65
Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol (2004) 1.64
Intravital imaging of amyloid plaques in a transgenic mouse model using optical-resolution photoacoustic microscopy. Opt Lett (2009) 1.63
Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem (2005) 1.58
Matrix-protein-specific regulation of Cx43 expression in cardiac myocytes subjected to mechanical load. Circ Res (2005) 1.55
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol (2011) 1.51
Autophagy regulates pancreatic beta cell death in response to Pdx1 deficiency and nutrient deprivation. J Biol Chem (2009) 1.48
Interprotofilament interactions between Alzheimer's Abeta1-42 peptides in amyloid fibrils revealed by cryoEM. Proc Natl Acad Sci U S A (2009) 1.45
Effect of blood contamination on delta 450 bilirubin measurement: an in vitro comparison of two corrective methods. Clin Chem (2004) 1.37
Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int (2013) 1.37
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med (2012) 1.33
Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J (2012) 1.28
Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.26
A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2005) 1.24
Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab (2006) 1.21
Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med (2006) 1.21
Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J Biol Chem (2012) 1.18
Distinct pathways regulate expression of cardiac electrical and mechanical junction proteins in response to stretch. Circ Res (2005) 1.18
Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist (2004) 1.18
TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci U S A (2008) 1.17
Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS One (2010) 1.17
Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy: a new experimental model of diabetic autonomic neuropathy. Am J Pathol (2003) 1.16
Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res (2006) 1.15
Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci U S A (2010) 1.14
Analysis of the Zucker Diabetic Fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic autonomic neuropathy. Am J Pathol (2003) 1.13
Evaluation of polymerase chain reaction for group B streptococcus detection using an improved culture method. Obstet Gynecol (2006) 1.13
ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice. Anesthesiology (2011) 1.11
Impact of a multidisciplinary intervention for diabetes in Eritrea. Clin Chem (2007) 1.11
Protein phosphatase 2A regulates bim expression via the Akt/FKHRL1 signaling pathway in amyloid-beta peptide-induced cerebrovascular endothelial cell death. J Neurosci (2006) 1.09
Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. J Neurosurg Spine (2006) 1.09
Evidence that CD147 modulation of beta-amyloid (Abeta) levels is mediated by extracellular degradation of secreted Abeta. J Biol Chem (2008) 1.07
Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc Natl Acad Sci U S A (2005) 1.07
Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care (2004) 1.07
Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes (2011) 1.06
Transmural distribution of connexins in rodent hearts. J Cardiovasc Electrophysiol (2004) 1.05
Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A (2006) 1.05
Vascular permeability precedes spontaneous intracerebral hemorrhage in stroke-prone spontaneously hypertensive rats. Stroke (2007) 1.04
Redistribution of connexin45 in gap junctions of connexin43-deficient hearts. Cardiovasc Res (2002) 1.03
Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep (2003) 1.02
A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med (2010) 1.02
Neuritic dystrophy and neuronopathy in Akita (Ins2(Akita)) diabetic mouse sympathetic ganglia. Exp Neurol (2008) 1.02
Ischemia-modified albumin increases after skeletal muscle ischemia during arthroscopic knee surgery. Clin Chim Acta (2005) 1.01
Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. Proc Natl Acad Sci U S A (2009) 1.00
Development of a valid and reliable blood stasis questionnaire and its relationship to heart rate variability. Complement Ther Med (2013) 1.00
Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Mol Med (2009) 1.00
Temporal relationship between apparent diffusion coefficient and absolute measurements of cerebral blood flow in acute stroke patients. Stroke (2003) 0.98
ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs (2014) 0.97
Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J Neuropathol Exp Neurol (2004) 0.97
Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther (2005) 0.96
MR imaging of oxygen extraction and neurovascular coupling. Stroke (2013) 0.95
Differential expression of genes encoding constitutive and inducible 20S proteasomal core subunits in the testis and epididymis of theophylline- or 1,3-dinitrobenzene-exposed rats. Biol Reprod (2006) 0.95
Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev (2008) 0.95
Symptomatic patients with intraluminal carotid artery thrombus: outcome with a strategy of initial anticoagulation. J Neurosurg (2012) 0.95
Lentiviral transduction of murine oligodendrocytes in vivo. J Neurosci Res (2005) 0.94
A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol Med (2011) 0.94
Use of serum FSH to identify perimenopausal women with pituitary hCG. Clin Chem (2008) 0.92
Expression profiling identifies a molecular signature of reactive astrocytes stimulated by cyclic AMP or proinflammatory cytokines. Exp Neurol (2007) 0.92
Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? J Investig Med (2011) 0.92
Amyloid beta peptide increases DP5 expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes. J Neurochem (2006) 0.92
Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci U S A (2006) 0.92
Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med (2012) 0.91
Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol (2011) 0.90
Remodeling of gap junctions and slow conduction in a mouse model of desmin-related cardiomyopathy. Cardiovasc Res (2005) 0.90
Erythropoietin: not just about erythropoiesis. Lancet (2010) 0.90
Osmole gap in neurologic-neurosurgical intensive care unit: Its normal value, calculation, and relationship with mannitol serum concentrations. Crit Care Med (2004) 0.90
Cerebral amyloid angiopathy: progressive disruption of the neurovascular unit. Stroke (2008) 0.90
Carbamylated erythropoietin reduces radiosurgically-induced brain injury. Mol Med (2006) 0.89
Synaptic ultrastructural alterations anticipate the development of neuroaxonal dystrophy in sympathetic ganglia of aged and diabetic mice. J Neuropathol Exp Neurol (2008) 0.89
Combination therapy for ischemic stroke: potential of neuroprotectants plus thrombolytics. Am J Cardiovasc Drugs (2002) 0.89
Signal evolution and infarction risk for apparent diffusion coefficient lesions in acute ischemic stroke are both time- and perfusion-dependent. Stroke (2011) 0.88